Cochrane · systematic review · CD013136
Stimulant and non‐stimulant drug therapy for people with attention deficit hyperactivity disorder and epilepsy
Eaton, C, Yong, K, Walter, V, et al. · Cochrane Database of Systematic Reviews · 2022 · Cochrane Library
EpilepsyAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
12
current version
GRADE rated
9
No studies
3
Included studies
NR
No studies 3 · 25%Ungraded 0 · 0%Very low 0 · 0%Low 7 · 58.3%Moderate 2 · 16.7%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Osmotic‐release oral system methylphenidate compared to placebo for people with ADHD and epilepsy
Population: people with ADHD and epilepsy
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Seizure frequency Osmotic‐release oral system methylphenidate vs placebo | no estimate extracted | 1 study · 33 participants | Low Downgraded: risk of bias, indirectness |
Proportion of people withdrawing from treatment Osmotic‐release oral system methylphenidate vs placebo | RR 2.8 [1.14, 6.89] | 1 study · 33 participants | Moderate Downgraded: risk of bias |
Seizure severity Osmotic‐release oral system methylphenidate vs placebo | no estimate extracted | 1 study · 33 participants | Low Downgraded: risk of bias, indirectness |
Proportion of people experiencing 50% or greater reduction in seizure frequency Osmotic‐release oral system methylphenidate vs placebo | no estimate extracted | NR | No studies |
ADHD symptoms Osmotic‐release oral system methylphenidate vs placebo | no estimate extracted | 1 study · 33 participants | Low Downgraded: risk of bias, indirectness |
Proportion of people experiencing adverse drug events Osmotic‐release oral system methylphenidate vs placebo | no estimate extracted | 1 study · 33 participants | Moderate Downgraded: risk of bias |
Omega‐3 (with risperidone and previous ASM) compared to risperidone and previous ASM only for people with ADHD and epilepsy
Population: people with ADHD and epilepsy
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Seizure frequency (monthly, postintervention) Omega‐3 (with risperidone and previous ASM) vs risperidone and previous ASM only | no estimate extracted | 1 study · 56 participants | Low Downgraded: risk of bias, imprecision |
Proportion of individuals withdrawing from treatment Omega‐3 (with risperidone and previous ASM) vs risperidone and previous ASM only | RR 0.65 [0.12, 3.59] | 1 study · 61 participants | Low Downgraded: risk of bias, imprecision |
Seizure severity Omega‐3 (with risperidone and previous ASM) vs risperidone and previous ASM only | no estimate extracted | NR | No studies |
Proportion of people achieving 50% or greater reduction in monthly seizure frequency (change from baseline) Omega‐3 (with risperidone and previous ASM) vs risperidone and previous ASM only | RR 2.79 [0.84, 9.24] | 1 study · 56 participants | Low Downgraded: risk of bias, imprecision |
ADHD symptoms Omega‐3 (with risperidone and previous ASM) vs risperidone and previous ASM only | no estimate extracted | NR | No studies |
Proportion of people experiencing adverse drug events Omega‐3 (with risperidone and previous ASM) vs risperidone and previous ASM only | RR 1.4 [0.44, 4.42] | 1 study · 56 participants | Low Downgraded: risk of bias, imprecision |